Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cara Therapeutics (CARA)
NASDAQ:CARA
Cara Therapeutics (CARA) Stock Price & Analysis
2,181 Followers
CARA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.50 - $4.67
Previous Close$0.71
Volume184.14K
Average Volume (3M)667.10K
Market Cap
$38.81M
Enterprise Value-$32.42M
Total Cash (Recent Filing)$78.54M
Total Debt (Recent Filing)$7.31M
Price to Earnings (P/E)-0.3
Beta1.68
Next Earnings
May 06, 2024EPS Estimate
-$0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.19
Shares Outstanding54,656,413
10 Day Avg. Volume401,493
30 Day Avg. Volume667,098
Standard Deviation0.19
R-Squared0.04
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.45
Price to Sales (P/S)11.88
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-1.65
Enterprise Value/Gross Profit-0.94
Enterprise Value/Ebitda0.30
Forecast
1Y Price Target
$6.20Price Target Upside747.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Cara Therapeutics News
PremiumCompany Announcements
Cara Therapeutics CMO Resigns for New Opportunity
PremiumCompany Announcements
Cara Therapeutics Is Worried About This – Should You Be Worried Too?
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressEnrollment in KOURAGE NP program progressing ahead of schedule, indicating a potential acceleration of Korsuva's development timeline.
Drug DevelopmentCara's focus on notalgia paresthetica (NP) represents its best risk-reward opportunity with no FDA-approved therapies currently available.
Market OpportunityThe significant unmet need in NP suggests a large market opportunity for Korsuva.
Bears Say
Drug Development ChallengesCompany has faced prior disappointments with its drug launches and trials.
Operational DownsizingThe company announced a significant workforce reduction by approximately 50%.
Program CancellationDiscontinuing the ongoing oral Korsuva Ph3 program in CKD-Pruritus.
---
Ownership Overview
14.28% Insiders
15.59% Mutual Funds
8.42% Other Institutional Investors
61.71% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CARA FAQ
What was Cara Therapeutics’s price range in the past 12 months?
Cara Therapeutics lowest stock price was $0.50 and its highest was $4.67 in the past 12 months.
What is Cara Therapeutics’s market cap?
Currently, no data Available
When is Cara Therapeutics’s upcoming earnings report date?
Cara Therapeutics’s upcoming earnings report date is May 06, 2024 which is in 18 days.
How were Cara Therapeutics’s earnings last quarter?
Cara Therapeutics released its earnings results on Mar 04, 2024. The company reported -$0.59 earnings per share for the quarter, missing the consensus estimate of -$0.446 by -$0.144.
Is Cara Therapeutics overvalued?
According to Wall Street analysts Cara Therapeutics’s price is currently Undervalued.
Does Cara Therapeutics pay dividends?
Cara Therapeutics does not currently pay dividends.
What is Cara Therapeutics’s EPS estimate?
Cara Therapeutics’s EPS estimate is -$0.4.
How many shares outstanding does Cara Therapeutics have?
Cara Therapeutics has 54,656,414 shares outstanding.
What happened to Cara Therapeutics’s price movement after its last earnings report?
Cara Therapeutics reported an EPS of -$0.59 in its last earnings report, missing expectations of -$0.446. Following the earnings report the stock price went down -9%.
Which hedge fund is a major shareholder of Cara Therapeutics?
Among the largest hedge funds holding Cara Therapeutics’s share is Farallon Capital Management, L.L.C.. It holds Cara Therapeutics’s shares valued at 1M.
---
Cara Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.20 (747.11% Upside)
$6.20 (747.11% Upside)
Blogger Sentiment
Neutral
CARA Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 295.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 9.1%
Last 30 Days ▼ 9.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.23%
12-Months-Change
Fundamentals
Return on Equity
-109.80%
Trailing 12-Months
Asset Growth
-30.94%
Trailing 12-Months
Company Description
Cara Therapeutics
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics. Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.
---
CARA Earnings Call
Q4 2024
0:00 / 0:00
---
CARA Stock 12 Months Forecast
Average Price Target
$6.20
▲(747.11% Upside)
Technical Analysis
Best Analysts Covering CARA
1 Year
1 Year Success Rate
5/15 ratings generated profit
1 Year Average Return
-25.29%
reiterated a buy rating 4 months ago
Copying Annabel Samimy's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -25.29% per trade.
---